[HTML][HTML] PCSK9 inhibitors: a new era of lipid lowering therapy
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …
(CVD). The recent American College of Cardiology and American Heart Association …
[PDF][PDF] WJC
R Chaudhary, J Garg, N Shah, A Sumner - World, 2017 - researchgate.net
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …
(CVD). The recent American College of Cardiology and American Heart Association …
PCSK9 inhibitors: A new era of lipid lowering therapy.
R Chaudhary, J Garg, N Shah… - World Journal of …, 2017 - europepmc.org
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …
(CVD). The recent American College of Cardiology and American Heart Association …
[PDF][PDF] WJC
R Chaudhary, J Garg, N Shah, A Sumner - World, 2017 - pdfs.semanticscholar.org
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …
(CVD). The recent American College of Cardiology and American Heart Association …
PCSK9 inhibitors: A new era of lipid lowering therapy
R Chaudhary, J Garg, N Shah… - World journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …
(CVD). The recent American College of Cardiology and American Heart Association …
[PDF][PDF] WJC
R Chaudhary, J Garg, N Shah, A Sumner - World, 2017 - scholarlyworks.lvhn.org
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …
(CVD). The recent American College of Cardiology and American Heart Association …
[PDF][PDF] WJC
R Chaudhary, J Garg, P Krishnamoorthy, K Bliden… - World, 2017 - academia.edu
World Journal of Cardiology Page 1 Erythropoietin therapy after out-of-hospital cardiac arrest: A
systematic review and meta-analysis Rahul Chaudhary, Jalaj Garg, Parasuram Krishnamoorthy …
systematic review and meta-analysis Rahul Chaudhary, Jalaj Garg, Parasuram Krishnamoorthy …
[引用][C] PCSK9 inhibitors: A new era of lipid lowering therapy
R Chaudhary, J Garg, N Shah, A Sumner - World Journal of Cardiology, 2017 - cir.nii.ac.jp
PCSK9 inhibitors: A new era of lipid lowering therapy | CiNii Research CiNii 国立情報学研究所
学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
[PDF][PDF] WJC
R Chaudhary, J Garg, P Krishnamoorthy, K Bliden… - World, 2017 - academia.edu
World Journal of Cardiology Page 1 Erythropoietin therapy after out-of-hospital cardiac arrest: A
systematic review and meta-analysis Rahul Chaudhary, Jalaj Garg, Parasuram Krishnamoorthy …
systematic review and meta-analysis Rahul Chaudhary, Jalaj Garg, Parasuram Krishnamoorthy …
[PDF][PDF] WJC
R Chaudhary, J Garg, P Krishnamoorthy, K Bliden… - …, 2017 - pdfs.semanticscholar.org
World Journal of Cardiology Page 1 Erythropoietin therapy after out-of-hospital cardiac arrest: A
systematic review and meta-analysis Rahul Chaudhary, Jalaj Garg, Parasuram Krishnamoorthy …
systematic review and meta-analysis Rahul Chaudhary, Jalaj Garg, Parasuram Krishnamoorthy …